Cardio Diagnostics Holdings, Inc. reported its financial results for the quarter ending June 30, 2025, revealing a revenue of $7,475, a slight decrease from $7,870 in the same quarter of the previous year. For the first half of 2025, the company generated $8,415 in revenue, significantly down from $23,798 in the first half of 2024. The decline in revenue is attributed to the conclusion of a testing initiative with Family Medicine Specialists, although the company noted that additional providers are being onboarded, which may positively impact future revenue.
The company's net loss for the second quarter of 2025 was $1,683,199, compared to a loss of $1,287,995 in the same period last year, marking an increase in losses primarily due to higher selling, general, and administrative expenses. For the first half of 2025, the net loss was $3,318,263, a decrease from $5,451,579 in the first half of 2024, largely due to reduced stock compensation expenses. Total operating expenses for the second quarter were $1,686,174, up from $1,290,330 in the prior year, driven by increased personnel costs and legal expenses.
In terms of operational developments, Cardio Diagnostics has been focusing on expanding its product offerings and market reach. The company launched its second product, PrecisionCHD™, in March 2023, and has been actively working on Medicare reimbursement processes for its tests. As of June 30, 2025, the company had 1,763,129 shares of common stock outstanding, reflecting a reverse stock split that took effect on May 12, 2025. The company has also been increasing its workforce to support its growth strategy, with a focus on hiring experienced sales personnel.
Looking ahead, Cardio Diagnostics aims to continue developing additional products and expanding its clinical and health economics evidence portfolio. The company plans to leverage newly awarded CPT PLA codes to enhance reimbursement efforts and is exploring market opportunities both domestically and internationally. Despite the challenges of long sales cycles, Cardio remains optimistic about increasing the adoption of its clinical solutions among healthcare providers and employers.
As of June 30, 2025, Cardio Diagnostics reported cash and cash equivalents of $7,966,500, a slight increase from $7,827,487 at the end of 2024. The company anticipates ongoing cash needs to support its operations and growth initiatives, and it plans to continue utilizing its at-the-market sales agreement to raise additional capital as needed. The management has acknowledged the potential for dilution of existing shareholders if additional equity is issued to meet funding requirements.
About Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. develops AI-driven epigenetic and genetic blood tests for cardiovascular disease risk assessment and early detection. Its flagship products, Epi+Gen CHD and PrecisionCHD, provide personalized insights to clinicians, payors, and health systems. The company aims to shift cardiovascular care from reactive to proactive, leveraging proprietary technology, strategic partnerships, and a broad market opportunity to improve prevention, diagnosis, and management of heart disease.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.